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Background: MicroRNA-196 (miR-196), which is highly up-regulated in oral cancer cells, has been reported to be
aberrantly expressed in several cancers; however, the significance of miR-196 in oral cancer has not yet been
addressed.
Methods: Cellular functions in response to miR-196 modulation were examined, including cell growth, migration,
invasion and radio/chemosensitivity. Algorithm-based studies were used to identify the regulatory target of
miR-196. The miR-196 target gene and downstream molecular mechanisms were confirmed by RT-qPCR, western
blot, luciferase reporter and confocal microscopy analyses. miR-196 expression was determined in paired cancer
and adjacent normal tissues from oral cancer patients.
Results: Both miR-196a and miR-196b were highly over-expressed in the cancer tissue and correlated with lymph
node metastasis (P = 0.001 and P = 0.006, respectively). Functionally, miR-196 actively promoted cell migration and
invasion without affecting cell growth. Mechanistically, miR-196 performed it's their function by inhibiting NME4
expression and further activating p-JNK, suppressing TIMP1, and augmenting MMP1/9.
Conclusion: miR-196 contributes to oral cancer by promoting cell migration and invasion. Clinically, miR-196a/b
was significantly over-expressed in the cancer tissues and correlated with lymph node metastasis. Thus, our findings
provide new knowledge of the underlying mechanism of cancer metastasis. miR-196 may serve as a promising
marker for better oral cancer management.
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In this study, we elucidated the significance of miR-196
in oral cancer. miR-196 promotes cell migration and in-
vasion. Mechanistically, miR-196 exerts these functions
by targeting to the NME4 molecule and regulating the
downstream JNK-TIMP1-MMP signaling pathway. In
addition, both miR-196a and miR-196b were remarkably
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ising marker for better management of oral cancer.Introduction
Oral cancer is one of the most prevalent cancers world-
wide [1]. Despite improvements in diagnosis and treat-
ment in recent decades, the survival rate for oral cancer
has not significantly changed due to the development of
distant metastases and therapeutic resistance [2-4]. It is
essential to thoroughly investigate the pathogenesis of
this disease to provide fundamental knowledge for future
clinical applications.
MicroRNAs (miRNAs) constitute an abundant class of
small, non-coding RNA molecules that regulate geneThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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repression or mRNA degradation [5]. Increasing evi-
dence indicates that miRNAs contribute to the develop-
ment of cancer by negatively regulating target gene
expression, and therefore they can function as tumor
suppressors or oncogenes [6,7]. Recently, miRNA
screening in several types of cancer has identified unique
expression profiles associated with specific tissues or
clinical features, including head and neck cancer [8,9].
To improve the understanding of the role of miRNAs in
oral cancer, we previously performed global miRNA pro-
filing of normal keratinocyte and cancer cell lines. We
discovered 23 miRNAs with significantly altered expres-
sion in cancer cells, including miR-196 [10]. miR-196
has been reported to be aberrantly expressed in various
malignancies, including melanoma, leukemia, and glio-
blastoma [11-21]. However, the underlying mechanism
by which these molecules cause malignancy remains
unclear.
In the present study, we characterized the function of
miR-196 and elucidated it’s molecular mechanism in oral
cancer. We found that the miR-196 family positively reg-
ulated cell invasion and migration, and had no effect on
cell growth. Mechanistically, miR-196 exerted their ef-
fects by directly targeting and inhibiting non-metastatic
cells 4 (NME4) protein expression to regulate the JNK-
TIMP1-matrix metalloproteinase (MMP) signaling path-
way. We revealed that both miR-196a and miR-196b
were highly over-expressed in the cancer tissues of pa-
tients with oral cancer, demonstrating the clinical signifi-
cance of these molecules during cancer progression.
Materials, subjects, and methods
Cells and cell lines
Four oral cancer cell lines (OECM1, SAS, CGHNC8,
and CGHNC9) and two normal keratinocyte cell lines
(CGHNK2 and CGHNK4) were used [10]. CGHNK2
and CGHNK4 cells are HPV-immortalized lines of nor-
mal keratinocytes that were described previously [10].
The immortalized normal keratinocyte cells were main-
tained in KSFM medium (Life Technologies, Inc., Gibco
BRL, Rockville, MD, USA). The cancer cell lines were
grown in 100% DMEM or RPMI 1640 medium contain-
ing 10% fetal bovine serum (Life Technologies, Inc.). All
cells were cultured at 37°C in a humidified atmosphere
with 5% CO2.
Cloning and transfection of miR-196–specific plasmids
and inhibitory antagomir oligonucleotides
All the oligonucleotides used in this study, including the
specific stem-loop sequences of miR-196a, miR-196b,
the inhibitory antagomir oligonucleotides (Anti-196a
and Anti-196b), random sequence for antagomir control
(RC) are listed in Additional file 1: Table S1. The stem-loop oligonucleotides were inserted into the multiple
cloning site of the pcDNA 3.1(+) expression vector
(Invitrogen, Carlsbad, CA, USA) to construct the miR-
196 overexpression plasmids. To promote miR-196 ex-
pression, 3 μg of miR-196 plasmid was transfected into
cells plated in 100-mm dishes. The miR-196a, miR-196b
antagomir and the random sequence oligonucleotides
for controls were purchased from TRI-I Biotech, Inc.
(New Taipei City, Taiwan). To suppress miR-196 expres-
sion, 300 μM antagomir oligonucleotides were trans-
fected into the cells. Transfection was performed using
the Lipofectamine 2000™ reagent (Invitrogen) in OPTI-
MEM medium (Invitrogen), and the cells were incubated
at 37°C in a humidified atmosphere with 5% CO2 for
10 h, similarly as previously described [22]. Afterward,
the medium was replaced with fresh complete medium,
and the cells were continuously cultured.
Cell migration assay
Cell migration was determined using an in vitro wound
healing assay as previously described [23]. After transfec-
tion of the miR-196 overexpression plasmids or the
antagomir oligonucleotides, 3.5 × 104 cells were seeded
in ibidi® culture inserts (ibidi LLC, Verona, WI, USA) on
top of a 6-well plate. After 8 h of incubation, the culture
inserts were detached to form a cell-free gap in the cell
monolayer. After changing to culture medium contain-
ing 1% FCS, cell migration of toward the gap area was
photographed every 6 h. All the experiments were per-
formed at least three times independently and that typ-
ical results were shown. In each sample, the invasion
ability was quantified by comparing the distance of the
cell-free gap after normalization to the control group.
The error bars shown in the relevant figures indicated
the standard deviation of the quantification results in all
experiments.
Cell invasion assay
The invasive abilities of the cells were determined by
culturing the cells on a polycarbonate membrane coated
with Matrigel (Becton Dickinson Biosciences, Franklin
Lakes, NJ, USA) in a Millicell invasion chamber (Millipore,
Billerica, MA, USA) as previously described [23].
Briefly, Matrigel was first coated onto the membrane of
the Millicell upper chamber for 12 h at 37°C. After
transfection of the miR-196 overexpression plasmids or
antagomir oligonucleotides, the cells were seeded in the
upper chamber with 1% FBS medium. The lower cham-
ber contained complete culture medium (containing
10% FBS) to trap invading cells. After incubation at 37°C,
the cells that invaded through the Matrigel-coated
membranes into the lower chamber were stained with
crystal violet and photographed. All the experiments
were performed at least three times independently and
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vasion ability was quantified by comparing the density
of crystal violet dye after normalization to the control
group. The error bars shown in the relevant figures indi-
cated the standard deviation of the quantification results
in all experiments.
mRNA and miRNA analysis by reverse transcription-
quantitative PCR (RT-qPCR)
Total RNA was isolated from cells using TRIzol reagent
(Gibco BRL). For mRNA determination, RT was per-
formed as previously described [24]. For miRNA deter-
mination, the revere transcription was performed as
previously described [10] using miR-196–specific stem-
loop RT primers and assay kits (ABI, Forest City, CA,
USA) according to the manufacturer’s suggested proto-
col. The PCR primers used for target genes are list in
Additional file 1: Table S1. The results of real-time PCR,
recorded as threshold cycle numbers, were normalized
against an internal control (U6 RNA for miRNAs or
GAPDH for mRNA). The comparative threshold cycle
(ΔΔCt) method was used to determine the gene expres-
sion. All the experiments were performed duplicate for
at least three times. The error bars shown in the relevant
figures indicated the standard deviation of the quantifi-
cation results in all experiments.
Protein extraction and western blot analysis
Protein extraction and western blot analysis were per-
formed as previously described [25]. Briefly, cellular pro-
teins were extracted using lysis buffer by incubating the
cells on ice for 30 min. Samples were centrifuged at
14,000 g for 30 min, and the supernatant was collected.
The protein samples were boiled at 95°C for 5 min, sepa-
rated by electrophoresis on 10% polyacrylamide gels
containing 0.1% SDS, and transferred to nitrocellulose
membranes. The membranes were incubated with pri-
mary followed by horseradish peroxidase-conjugated
secondary antibodies. The primary antibodies used in
this study are listed in Additional file 1: Table S2. The
membranes were developed using an ECL developing so-
lution (Millipore) followed by autoradiography. All the
experiments were performed at least three times inde-
pendently and that typical results were shown. In each
sample, the protein expression shown in each band was
quantified after normalization to the GAPDH expression
level. The error bars shown in the relevant figures indi-
cated the standard deviation of the quantification results
in all experiments.
Luciferase reporter assay for the NME4 3′-UTR
The pMIR-REPORT firefly luciferase vector plasmid
(pMIR, Ambion, Grand Island, NY, USA) was used. The
3′-UTR region of wide-type NME4 was amplified byPCR and cloned downstream of the luciferase vector
(p-UTR-WT). A mutant sequence was also cloned as a
validation plasmid (p-UTR-mut). pMIR, p-UTR-WT,
and p-UTR-mut was co-transfected with the miR-196–
specific antagomirs or overexpression plasmids into
OECM1 or SAS cells. The pRL-SV vector (Promega,
Madison, Wisconsin, USA) containing Renilla luciferase
was also transfected for each condition as a reference
control. Firefly and Renilla luciferase activities were
measured using the Dual-Luciferase Reporter Assay Sys-
tem (Promega) according to the manufacturer’s instruc-
tions [26]. All the experiments were performed triplicate
for at least three times, and the similar results were ob-
tained. The error bars shown in the relevant figures indi-
cated the standard deviation of a triplicate experiment.Immunofluorescence staining and confocal microscopy
Immunofluorescence staining and confocal microscopy
were performed as previously described [27]. Briefly,
cells were seeded onto coverslips coated with poly-L-
lysine and incubated overnight at 37°C. After washing,
the cells were fixed with formaldehyde, permeabilized
with a permeation buffer, and blocked with 1% FBS.
After overnight incubation with primary antibodies, the
coverslips were incubated with fluorescence-conjugated
secondary antibodies (Molecular Probes, Invitrogen,
Carlsbad, CA, USA). The coverslips were then mounted
with mounting medium containing DAPI dye (Vector
Laboratories, Burlingame, CA, USA), and the fluores-
cence was visualized using a confocal laser microscope
(Leica TCS Sp2 MP).Patients and clinical association study and statistical
analysis
This study was approved by the Institutional Review
Broad of the Human Investigation Committee in Chang
Gung Memorial Hospital. Written informed consent was
obtained from all patients participating in this study.
Fifty-four patients who visited Chang Gung Memorial
Hospital (Taoyuan, Taiwan) were recruited for this study.
The characteristics of these patients are summarized in
Table 1. This study consisted of 5 (9%) females and 49
(91%) males. The mean age of the patients was 54.6 years
old, with a median age of 53.0 years (range, 35–77
years). A total of 25 patients (46%) consumed alcohol,
30 patients (56%) smoked cigarettes, and 37 (68%)
chewed betel quid. Cancer lesions were in oral tongue
(n = 19, 35%), buccal mucosa (n = 17, 32%), other oral
cavity sites (n = 17, 31%), or soft plate (n = 1, 1.9%). The
surgically dissected cancer tissues and small pieces of
adjacent normal counterpart were obtained before
chemotherapy or radiotherapy. Twenty patients (37%)
were receiving radical surgery, and 13 (24%) and 21
Table 1 Characteristics 54 patients with oral cancer, and
the association of miR-196a and miR-196b expressions
with clinicopathological status
miR-196a miR-196b
Characteristics (n) low (n,%) high (n,%) low (n,%) high (n,%)
Sex
Female (5) 0 (0) 5 (100) 1 (20) 4 (80)
Male (49) 12 (24) 37 (76) 18 (37) 31 (63)
*P value 0.210 0.455
Age
≤ 55 years old (30) 6 (20) 24 (80) 9 (30) 21 (70)
> 55 years old (24) 6 (25) 18 (75) 10 (42) 14 (58)
P value 0.661 0.372
Alcohol drinking
No (29) 6 (21) 23 (79) 10 (34) 19 (66)
Yes (25) 6 (24) 19 (76) 9 (36) 16 (64)
P value 0.770 0.907
Cigarette smoking
No (24) 3 (12) 21 (88) 7 (29) 17 (71)
Yes (30) 9 (30) 21 (70) 12 (40) 18 (60)
P value 0.124 0.407
Betel quid chewing
No (17) 3 (18) 14 (82) 7 (41) 10 (59)
Yes (37) 9 (24) 28 (76) 12 (32) 25 (68)
P value 0.584 0.532
Pathologic T-status
T1-T2 (25) 6 (24) 19 (76) 9 (36) 16 (64)
T3-T4 (29) 6 (21) 23 (79) 10 (34) 19 (66)
P value 0.770 0.907
Pathologic N-status
pN0 (32) 12 (37) 20 (63) 16 (50) 16 (50)
pN + (22) 0 (0) 22 (100) 3 (14) 19 (86)
*P value 0.001 0.006
Pathologic stage
I - II (19) 6 (32) 13 (68) 8 (42) 11 (58)
III - IV (35) 6 (17) 29 (83) 11 (31) 24 (69)
P value 0.223 0.433
Differentiation
Well (15) 5 (33) 10 (67) 6 (40) 9 (60)
Moderate (35) 7 (20) 28 (80) 13 (37) 22 (63)
Poor (4) 0 (0) 4 (100) 0 (0) 4 (100)
#P value 0.137 0.280
Total 12 (22) 42 (78) 19 (35) 35 (65)
*Fisher’s exact test was used.
#Liner-by-linear association test was used.
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apy and concomitant chemoradiotherapy, respectively.
For each tissue, total RNA was extracted and subjected
to miR-196a and miR-196b analyses as described previ-
ously. To define the relative levels of miR-196 in the
clinical samples, the expression level of each tumor sam-
ple was normalized to an internal control (U6 RNA) and
compared with that of normal tissue from the same pa-
tient. The cutoff points were determined after calculat-
ing the receiver operating characteristic (ROC) curve for
best fit of sensitivity and specificity. Expression levels
greater than 15-fold for miR-196a and 7-fold for miR-
196b in tumor tissues compared to the expression in
normal tissue were defined as ‘high.’ Level. The Pearson
chi-square test was used to examine the association of
miR-196 expression with clinicopathologic features, in-
cluding TNM stage. Survival curves were calculated by
the Kaplan-Meier method with a log-rank test. All P
values were two-sided, and the significance level was set
at P < 0.05.Results
Both miR-196a and miR-196b promote cell migration and
invasion without affecting cell growth
To determine the carcinogenic functions of miR-196a
and miR-196b, in vitro loss-of-function experiments
using antagomir oligonucleotides and gain-of-function
experiments using miRNA plasmid transfections were
performed. The results indicated that the antagomirs
against miR-196a and miR-196b substantially inhibited
their expression by 79–80 and 62–73%, respectively, in
OECM1 and SAS cells after 1 day (Figure 1A). Plasmid
transfection upregulated miR-196a and miR-196b levels
by 2.8–5.7- and 4.6–7.1-fold, respectively, in OECM1
and SAS cells after 1 day (Figure 1A). The potential ef-
fect of miR-196a or miR-196b on cell growth was exam-
ined in OECM1 and SAS cells. As shown in Additional
file 2: Figure S1, silencing of miR-196a or miR-196b had
no effect on cell proliferation. Similarly, over-expression
of miR-196a or miR-196b has no significant effect on
cell colony growth. These results suggested that miR-
196 has minimal effect on growth regulation.
The potential effect of miR-196 on and chemo/radio-
sensitivity was also examined using a clonogenic survival
assay. Silencing of miR-196a or miR-196b had no effect
on cell survival in response to cisplatin treatment
(Additional file 2: Figure S2A). However, miR-196a and
miR-196b had differential effects on radiosensitivity.
Whereas miR-196b depletion had no effect, both cell
lines were significantly more sensitive to radiation after
miR-196a silencing (Additional file 2: Figure S2B). This
result suggests that miR-196a, but not miR-196b, pro-
tects cells against radiation damage.
Figure 1 Both miR-196a and miR-196b promote migration and invasion without affecting cell growth. (A) Modulation of miR-196a and miR-196b
expression after transfection of specific antagomirs or over-expression plasmids into OECM1 and SAS cells. These included miR-196 antagomirs (Anti-196a,
Anti-196b), the random sequence for antigomir control (RC), the over-expression plasmids (miR-196a, miR-196b), or the expression vector (pcDNA). After
1 days of transfection, cells were harvested, and the levels of miR-196a and miR-196b were determined as described in the Methods section. (B) Effect
of miR-196 modulation on cell growth and colony formation. After transfection of miR-196–specific antagomirs (Anti-196a, Anti-196b) or random
oligonucleotides (RC) for 1 day, 1 × 106 cells were re-seeded in 100 mm plates with for 3 days to allow cell growth, or 1 × 105 cells were seeded for
7 days to allow colony formation. The number of colonies was determined. (C) Cells after modulating miR-196 level were applied to an in vitro wound
healing migration assay as described in the Methods section. Cell migration toward the gap was observed, photographed, and quantified at the indicated
times. (D) Effects of miR-196 modulation on cell invasion. After the transfection of miR-196 overexpression plasmids or the antagomir oligonucleotides,
cells were subjected to a Matrigel invasion assay as described in the Methods section. The cells that invaded through the Matrigel-coated membranes to
the lower chamber were stained, photographed, and quantified at the indicated times. (*p < 0.05 , **p < 0.01, ***p< 0.005, t-test).
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in vitro wound healing and Matrigel invasion assays. As
shown in Figure 1B, miR-196 silencing resulted in slower
migration toward the gap area in both OECM1 and SAS
cells, with reductions of 28-50% and 41-62%, respect-
ively, for miR-196a and miR-196b at 12 hours. Consist-
ently, miR-196 over-expression significantly enhanced
cell migration in both cell lines, with 1.9-2.7- and 1.7-
2.2-fold increases, respectively, for miR-196a and miR-
196b at 9 hours. Similar effects were also observed in
cell invasion ability (Figure 1C). Depletion of miR-196a
or miR-196b dramatically reduced the invading cells by
40-50% in both OECM1 and SAS cells. Consistently,
miR-196a or miR-196b over-expression significantly
enhanced cell invasion by 2.2-fold in both cell lines.
Supporting these cellular findings, the expressions of cell
adhesion molecules N-cadherin and fibronectin were
up-regulated in the miR-196 over-expressing cells
(Figure 1D). Collectively, miR-196a and miR-196b
promote migration and invasion in oral cancer cells
but exhibit minimal effects on cell growth.
NME4 is a direct regulatory target of miR-196
To identify the potential target of miR-196, computa-
tional prediction software, including PicTar, miRanda,
and TargetScan, was used. These programs identified
common candidates for both miR-196a and miR-196b
(Additional file 2: Figure S3). The expression of these
genes was further confirmed by RT-qPCR in response to
miR-196 modulation. Four genes (ABCB9, HOXA5,
MGATA4, and NME4) were upregulated by more than
20% after miR-196 depletion, whereas three genes
(HOXB6, SMCR8, and NME4) were downregulated by
more than 20% after miR-196 overexpression (Additional
file 2: Figure S3). Of these genes, only the expression of
NME4 changed consistently in both confirmation studies.
Therefore, NEM4 is a potential miR-196 regulatory target.
To determine the association of miR-196 and NME4,
the expression levels of these molecules were examined
in two lines of normal keratinocytes and four oral cancer
cell lines. As shown in Figure 2A, miR-196 was signifi-
cantly up-regulated in all cancer cell lines compared to
those in normal cells, with 92- and 71-fold higher in
average for miR-196a and miR-196b respectively. By
contrast, NME4 expression was reduced in all cancer
cell lines at both mRNA (3.9 fold) and protein levels (2.3
fold) (Figure 2B). This reverse correlation between these
molecules further suggests that NME4 is a regulatory
target of miR-196 (Figure 2C).
To further examine whether NME4 is a down-stream
target of miR-196, the potential effect of NME4 protein
expression was determined in response to miR-196
modulation. As shown in the Figure 2D, NME4 levels
were elevated (1.4–2.9-fold) or reduced (52–78%) uponmiR-196 silencing or over-expression. To validate the
regulatory target of NME4, a luciferase reporter assay
was performed. Reporter plasmids that carry human
NME4-3’UTR wild-type sequence (p-UTR-WT) and
mutant sequence (p-UTR-mut) (Figure 2E) were
co-transfected with either miR-196 antagomirs or ex-
pression plasmids. Silencing miR-196a or miR-196b in-
creased NME4 wild-type UTR reporter activity in both
OECM1 (1.7–2.0-folds) and SAS (1.3-fold) cells but
had no effect on mutant UTR or empty vector reporter
activity. Consistently, over-expression of miR-196a or
miR-196b reduced NME4 wild-type UTR reporter
activity both cell lines (by 57% in OECM1 cells and
29-36% in SAS cells). However, these miR-196 modula-
tions exhibited minimal effects on mutant UTR reporter
activity (Figure 2E). Taken together, these results sug-
gest that NME4 is a down-stream regulatory target of
miR-196.
NME4 suppressed the effects of miR-196 on cell migration
and invasion
To investigate whether the enhancement of cell migra-
tion and invasion by miR-196 occurred via the suppres-
sion of NME4, these cellular effects were analyzed upon
exogenous expression of NME4 in miR-196–over-
expressing cells. After verifying the expression status of
miR-196 and NME4 upon specific plasmid transfection
(Figure 3A), cell invasion and migration were examined
(Figure 3B-C). MiR-196 transfection significantly pro-
moted cell invasion (2.3-fold) and migration (2.1-fold).
However, cell invasion (Figure 3B) and migration
(Figure 3C) were inhibited by 39 and 43%, respectively,
upon exogenous NME4 expression. Transfection of
NME4 alone had no effect on cell invasion or migration.
Hence, the effect of miR-196 on cell migration and inva-
sion is NME4-dependent.
Cellular function of miR-196 occurs through the NME4-JNK-
TIMP1-MMP1/9 molecular pathway
The mitogen-activated protein kinase (MAPK) pathway
has been well characterized and demonstrated to play an
important role in cell mobility [28,29]. We investigated
whether the effect of the miR-196–NME4 axis on cellu-
lar functions was regulated by MAPK molecules. Pos-
sible alterations in the phosphorylation status on three
MAPK molecules, JNK, Erk, and p38, were examined by
immunoblotting upon the modulation of miR-196 or
NME4 expression via plasmid transfection. As shown in
Figure 4A, miR-196 and NME4 had minimal effects on
phospho-Erk (p-Erk) and phospho-p38 (p-p38) levels.
However, phospho-JNK (p-JNK) levels were significantly
increased by 2.6- and 1.8-fold by miR-196a and miR-
196b modulation, respectively, whereas p-JNK levels
were reduced to 0.7-fold of control levels by NME4
Figure 2 NME4 is a direct regulatory target of miR-196. (A) Differential expression of miR-196a/b and NME4 mRNA in two immortalized
normal keratinocyte and four oral cancer cell lines, as determined by RT-qPCR. Relative levels of miR-196a/b were determined after normalization
to the U6 RNA level (internal control) for each sample. The NME4 RNA level was normalized to actin for each sample. (B) Differential expression
of NME4 mRNA and protein in two immortalized normal keratinocyte and four oral cancer cell lines, as determined by RT-PCR and western
blotting. Actin expression was also determined as an internal control. (C) Inverse correlation between NME4 and miR-196a/b expression which
determined by RT-qPCR. (D) Effect of miR-196 modulation on NME4 mRNA expression. OECM1 and SAS cells transfected with miR-196a/b–specific
antagomirs or overexpression plasmids were harvested. Total protein was extracted and subjected to western blot analysis of NME4 expression.
The relative expression was determined after normalization to actin as an internal control. (E) The mature sequences of miR-196a and miR-196b,
as well as the 3′-UTR sequence of the human NME4 gene, are shown. The mutant sequence of the 3′-UTR region of NEM4 was designed. Luciferase
reporter assay was performed to determine whether NME4 is a direct miR-196a/b target gene. Cells transfected with miR-196–specific antagomirs or
overexpression plasmids were co-transfected with pMIR, p-UTR-WT, or p-UTR-mut. Renilla luciferase was also transfected as a reference control for each
condition. Firefly and Renilla luciferase activities were measured using the dual-luciferase reporter assay. (*p < 0.05 , **p < 0.01, ***p < 0.005, t-test).
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Figure 3 NME4 suppressed the effect of miR-196s on cell migration and invasion. (A) Verification of the expression status of miR-196 s and
NME4 after transfection of the miR-196 overexpression or NME4 plasmids. After the transfection of miR-196 and/or NME4 plasmids into OECM1
cells, cell invasion (B) and migration (C) were examined as described in the Methods section. The empty vectors (pcDNA for miR-196 and pCIneo
for NME4) were added if necessary to make total DNA amount being equally used in all experiments. (*p < 0.05, **p < 0.01, ***p < 0.005, t-test).
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NME4 axis stimulates JNK phosphorylation.
The MMP family of proteins (MMP1, MMP2, and
MMP9) and their tissue inhibitor TIMP1, which can pro-
mote or inhibit the digestion of the extracellular matrix
[30,31] were also examined (Figure 4A). Consistently, ex-
ogenous expression of miR-196a or miR-196b suppressed
TIMP1 expression and enhanced MMP1 and MMP9 ex-
pression. Consistently, exogenous NME4 elevated TIMP1
expression but suppressed MMP1 and MMP9 expression.
These results suggest that miR-196 promotes cell invasion
through the NME4-JNK pathway, leading to the suppres-
sion of TIMP1 activity and elevation of MMP1/9 activity.
To determine whether JNK phosphorylation affects
MMP expression, the JNK inhibitor SP600125 was used.
As shown in Additional file 2: Figure S5, the treatment
with SP600125 (0–50 μM) suppressed phospho-c-Jun
(p-c-Jun) expression with a concomitant increase inTIMP1 expression and decrease in MMP1/9 expression.
These concentration-dependent alterations suggest that
TIMP1 and MMP1/9 are downstream targets of p-JNK
and p-c-Jun.
To validate the regulation of the miR-196-NME4-pJNK-
TIMP-MMP pathway, immunofluorescence staining and
confocal microscopy were performed. As shown in
Figure 4B, exogenous miR-196 reduced NME4 expression
and elevated p-JNK and MMP9 expression compared to
the findings in the control. On the contrary, exogenous
NME4 reduced p-JNK and MMP9 expression. Introduction
of NME4 in miR-196–overexpressing cells reversed the ef-
fect of miR-196 on p-JNK and MMP9 expression. Further-
more, this molecular pathway was also confirmed in
another oral cell line (SAS) (Additional file 2: Figure S6).
Taken together, these results suggest that miR-196 exerts
it's effect through the NME4-pJNK-TIMP1-MMP1/9 path-
way (Figure 4C).
Figure 4 Cellular effect of miR-196 is exerted via the NME4-JNK-TIMP1-MMP1/9 molecular pathway in OECM1 cells. (A) Effects of miR-196 or
NME4 plasmid transfection on MAPK, TIMP1 and MMP protein expression in OECM1 cells. Protein expression was determined by western blot analysis,
and the density of each band was quantified. (B) Effect of miR-196 or NME4 plasmid transfection on p-JNK and MMP9 expression in OECM1 cells.
Protein expression was determined by immunofluorescence staining and confocal microscopy. (C) A hypothetical model illustrating the
miR-196-NME4-JNK-TIMP1-MMP1/9 molecular signaling pathway in oral cancer. (*p < 0.05, **p < 0.01, ***p < 0.005, t-test).
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tissues correlates with the clinical N-stage
To understand the clinical significance of miR-196, nor-
mal and cancerous tissues from 54 patients with oral can-
cer were obtained for analysis. For each tissue sample, therelative miRNA levels were determined, and the results
are shown in Figure 5. Both miR-196a and miR-196b were
substantially overexpressed in the cancer tissues. Com-
pared to their normal counterparts, 96.3 (52 of 54) and
88.6% (48 of 54) of the cancer tissues exhibited greater
Figure 5 High expression of miR-196a and miR-196b in cancer tissues. A total of 54 paired cancer (T) and adjacent normal (N) tissues were
obtained from patients with oral cancer. (A) For each sample, the expression levels of miR-196a and miR-196b were determined by RT-qPCR and
normalized to U6 RNA as an internal control. (B) The relative expression of each sample is illustrated. The scatter dot plot shows the relative levels of
miR-196a and miR-196b in the cancer and normal tissues from the patients. (C-D) Six paired of normal and oral cancer tissues were examined. (C) The
expression level of miR-196a and miR-196b in the pairs of sample were determined by RT-qPCR based method. (D) The protein expressions of NME4,
p-JNK and MMP9 were determined by western blot method, and showing GAPDH level as an internal control. Relative expressions of NME4, pJNK and
MMP9 in each paired tissues. The density of each protein band was quantified after normalization to the GAPDH in each sample. The lines indicate the
tendency of altered expressions of NME4, pJNK and MMP9 in each paired tissues. (*p < 0.05, **p < 0.01, ***p < 0.005, t-test).
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(Figure 5A), respectively. On average, miR-196a and miR-
196b levels were elevated by 59.1- and 10.4-fold, respect-
ively, in the cancer tissues (Figure 5B).
To determine miR-196 downstream regulatory mech-
anism in vivo, six paired normal and cancerous oral
cancer tissues were examined. As expected, miR-196a
and miR-196b were significantly over-expressed in all
cancer tissues (Figure 5C). Consistent with these cellular
findings, the NME4 target molecule was substantially
suppressed, and an elevation of phosphorylated JNK and
MMP9 protein expression was observed (Figure 5D).
These results confirmed that the dysregulation pathway
of miR-196-NME4-pJNK-MMP molecular axis occurring
in oral cancer patients.
To determine the potential association between cancer
status and miR-196 expression, Pearson’s chi-squared
test was used for statistical analysis. The associations of
miR-196 expression with cancer stage and pathological
status are shown in Table 1. There was no significant
correlation of miR-196 expression with the pathological
T stage, overall stage, differentiation status, alcohol con-
sumption, cigarette smoking, or betel quid chewing.
However, a significant correlation was found between
high miR-196 levels and the pathological N stage (P =
0.001 and P = 0.006 for miR-196a and miR-196b, re-
spectively). These results indicate the clinical signifi-
cance of the miR-196 molecules in oral cancer.
Discussion
The dysregulation of miRNAs is associated with malig-
nant transformation. Previously, miR-196 expression was
shown to be altered in several cancers. Although some
investigators have reported decreased miR-196 expres-
sion in cancers, others have observed increased miR-196
expression. For example, miR-196a and miR-196b are
down-regulated (or function as tumor suppressors) in
melanoma [11] and acute lymphoblastic leukemia [17,19].
However, miR-196a and miR-196b over-expression has
been observed in several malignant diseases, including
cancers of the esophagus [21], pancreas [20], colorectum
[12], glioblastoma [14], and several types of leukemia
[13,18,32]. High miR-196a levels have also been associated
with a poor prognosis in pancreatic cancer, glioblastoma,
and oral squamous cell carcinoma. Furthermore, the poly-
morphism of pre-miR-196a2 gene was observed in several
malignant diseases, including head and neck cancer, and
has been associated with cancer susceptibility or prognosis
[33-37]. These studies indicate that miR-196 dysregulation
plays an important role in carcinogenesis. Consistent with
other reports, we previously observed miR-196 overex-
pression in oral cancer cell lines [10]. In that study, we fur-
ther identified miR-196 overexpression in the cancer
tissues of approximately 90% of patients with oral cancercompared to their expression in normal tissue (Figure 5),
and this overexpression was associated with an aggressive
phenotype with lymph node invasion (Table 1). These re-
sults demonstrate the significance of miR-196 in the devel-
opment of oral cancer.
There are limited reports on the role of miR-196 in
cancer development. In a study of breast cancer, ectopic
miR-196a expression suppressed cell invasion, but the
expression level of miR-196 was not correlated with the
clinical metastatic status [15]. This result is different
from the findings in gastrointestinal cancers, in which
miR-196 overexpression promotes cell migration and in-
vasion in colorectal and gastric cancer cells [12,38,39].
In another study, transfection of miR-196a mimic oligo-
nucleotides into esophagus cells revealed that miR-196a
promoted cell proliferation and suppressed apoptosis
[40]. Thus far, the function of miR-196 in cancer re-
mains obscure. In this study, we determined the role of
miR-196 in oral cancer using both silencing and overex-
pression approaches. We found that both miR-196a and
miR-196b actively promoted cell migration and invasion
(Figure 1B-C), which were supported by the altered ex-
pression of fibronectin and N-cadherin (Figure 1D).
However, neither miR-196a nor miR-196b affected cell
growth and colony formation (Additional file 2: Figure
S1). Hence, the main function of the miR-196 family in
oral cancer is the regulation of cell mobility and
invasiveness.
Identification of the target molecules of these miRNAs
is of high interest. Previously, several molecules were re-
ported as regulatory targets of miR-196. HOX family
members have been reported primarily, including HOX-
B7 (miR-196a target) in melanoma [16], HOX-A (miR-
196b target) in acute lymphoblastic leukemia [18], and
HOX-C8 (miR-196 family target) in melanoma [11] and
breast cancer [15]. In this study, four HOX family genes
(HOXA5, HOXB6, HOXB7, HOXC8) were identified as
targets of miR-196. However, none of these genes
responded to miR-196 perturbation (Additional file 2:
Figure S4). This difference may be due to the distinct
tissue specificity among the various regulatory targets of
miR-196. In this study, after clarifying the correlation
between NME4 and miR-196 expression in cells
(Figure 2A-C), assessing the response of NME4 to
miR-196 modulation (Figure 2D), we identified NME4
as a direct target of miR-196a and miR-196b in oral
cancer using a luciferase reporter assay (Figure 2E),
NME4, also named nm23-H4, is a member of the
nm23 family [41]. The proteins in this family possess nu-
cleoside diphosphate kinase activity, which is believed to
be involved in DNA repair mechanisms [42]. Nm23 fam-
ily proteins also contain the RGD domain, as they can
bind to integrin, and this family has been postulated to
be involved in cell adhesion and migration [43]. Thus
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with cancer, but genomic aberration or altered gene ex-
pression has been observed for NME4 in several types of
cancers [44-47]. Although the function of NME4 is un-
clear, it was reported that an nm23 family member,
NEM1, is regulated by TP53 [48] and that it acts as a
metastatic suppressor [49]. In this study, we also found
that ectopic expression of NME4 has no significant ef-
fect on cell invasion and migration (Figure 3B-C), indi-
cating that a certain level of NME4 protein is sufficient
for maintaining cellular mobility. However, restoration
of silenced NME4 suppressed these effects induced by
miR-196 (Figure 3B-C), suggesting that NME4 partici-
pates in the miR-196 regulatory pathway by inhibiting
these functions. Collectively, miR-196 plays an onco-
genic role by degrading NME4, thus accelerating cell mi-
gration and invasion.
The downstream regulatory mechanism of the miR-196–
NME4 interaction was further investigated. In examining
three MAPK family molecules, we found that p-JNK, but
not p-Erk or p-p38, responded to miR-196 expression
and NME4 inhibition, whereas miR-196 and NME4 had
minimal effects on the expression of MAPK proteins
(Figure 4A). These results indicate that miR-196–NME4
signaling could result in JNK phosphorylation and activa-
tion. In addition, TIMP1 and MMP1/9 displayed opposite
responses to miR-196 suppression and NME4 augmenta-
tion (Figure 4A). These results suggest that TIMP1 and
MMP1/9 are the downstream regulatory molecules of the
miR-196–NME4 signaling axis. Additionally, we found that
p-JNK inhibition increased TIMP1 expression and de-
creased MMP1/9 expression (Additional file 2: Figure S5).
Hence, TIMP1 and MMP1/9 could be regulated by JNK
phosphorylation. Moreover, the role of the NME4-pJNK-
TIMP1-MMP1/9 signaling pathway in miR-196 function
was further demonstrated by immunofluorescence staining
and confocal microscopy (Figure 4B). Furthermore, this
molecular pathway was also confirmed in another oral cell
line (SAS) (Additional file 2: Figure S6) and paired normal
and cancerous oral cancer tissues (Figure 5D). Thus, miR-
196 appear to fine-tune the invasion mechanism in oral
cancer by inhibiting NME4, leading to the activation of p-
JNK and MMP1/9 and suppression of TIMP1 (Figure 4C).
In conclusion, we clarified that miR-196 promotes inva-
sive and migratory phenotypes in oral cancer. Mechanistic-
ally, miR-196 exerted its functions by targeting to NME4,
leading to the regulation of downstream molecules, includ-
ing activating p-JNK, suppressing TIMP1, and augmenting
MMP1/9. Consistently, clinical studies have revealed that
both miR-196a and miR-196b are remarkably up-regulated
in cancer tissue and correlated with lymph node metastasis.
Thus, our findings provide new knowledge of the under-
lying mechanism of cancer metastasis. miR-196 may serve
as a promising marker for better oral cancer management.Additional files
Additional file 1: Table S1. Names and sequences of oligonucleotides
of miR-196 stem-loop, the specific antigomirs and RT-PCR primers. Table
S2. The primary antibody used in this study.
Additional file 2: Figure S1. Both miR-196a and miR-196b has minimal
effect on cell growth and colony formation in OECM1 and SAS cells. (A)
After inhibition of miR-196s by antagomirs, cells were re-seeded to allow
cell growth, and cell numbers were measured. (B) Cells were transfected
with miR-196s over-expression plasmid to increase miR-196s expression.
Clonogenic assay were performed and the number of colonies was
determined. Figure S2. Neither miR-196a nor miR-196b affected
chemosensitivity, whereas only miR-196a protects cells against irradiation (A)
Chemoresistance was determined by the relative number of surviving cells
after treatment with serial concentrations (0–5 μg/ml) of cisplatin for 2 days.
In each sample, cell survival was counted and compared to the number
of surviving untreated cell. (B) Radioresistance was determined using a
clonogenic survival assay after treatment with various doses (0–6 Gy) of
radiation for 7 days. Figure S3. Bioinformatic prediction of the regulatory
targets of miR-196s using PicTar, TargetScan, and miRanda computational
prediction software. The shared genes predicted by the three different
prediction methods are listed in the table. Figure S4. Validation of the
predicted genes by RT-qPCR. After transfection of the miR-196 antagomirs
or overexpression plasmids into OECM1 cells, the mRNA level of each gene
was determined by RT-qPCR. Relative expression was determined after each
gene was normalized to the internal control (Actin). Figure S5. Effect of
the JNK phosphorylation inhibitor SP600125 on TIMP1 and MMP protein
expression in OECM1 cells. Protein expression was determined by western
blot. Figure S6. (A) Effects of miR-196s or NME4 plasmid transfection on
p-JNK, MMP1 and MMP9 in SAS cells. (B) Effect of the JNK phosphorylation
inhibitor SP600125 on MMP protein expression in SAS cells. Protein
expression was determined by western blot.
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